Historic Alzheimer’s Drug Infusion Marks New Hope in Canada

Sharon Runge has made history as the first patient in Canada to receive an infusion of a newly approved Alzheimer’s treatment, Lecanemab. This milestone, recognized by Health Canada, represents a significant advancement in the fight against Alzheimer’s disease. Cognitive Neurologist Dr. Sara Mitchell remarked on the importance of this moment, stating, “It’s a historic moment for people living with Alzheimer’s disease and their families in Canada because we have been able to meaningfully intervene in this disease.”

Canada Joins Global Efforts Against Alzheimer’s

Canada recently became the last of the G7 nations to approve Lecanemab, a monoclonal antibody designed to eliminate harmful amyloid plaques from the brain. Clinical studies have shown that this treatment can slow the progression of Alzheimer’s by approximately 30 percent. Dr. Mitchell explained that long-term data indicates that patients using this drug could experience an additional year of independent living over a four-year period.

For families like the Runges, the potential benefits of Lecanemab are profound. Dallard Runge, Sharon’s husband, expressed his hope that this new treatment would delay the progression of his wife’s condition. “The longer we have together, the more happiness we’ll get to share,” he said. Sharon was diagnosed with Alzheimer’s about a year ago, and this treatment offers a glimmer of hope in a challenging journey.

Funding Challenges for New Treatment

Despite its approval, Lecanemab has not yet received a funding recommendation from the Canada Drug Administration. As a result, provincial health agencies have not provided coverage for the drug, leaving families like the Runges responsible for the full cost of treatment. The estimated cost for biweekly infusions is around $32,000 per year, which varies based on the patient’s weight.

Dr. Mitchell emphasized the need for government support to ensure equitable access to Lecanemab for all Canadians. “There are people that you’ll see every day on the street who have this disease and who want to keep living independently. That’s who this drug is for,” she stated. However, the introduction of this costly treatment has faced some public resistance, with critics questioning the use of taxpayer funds for such an expensive drug.

Dallard Runge responded to this criticism by urging empathy, suggesting that those opposed to funding should “walk in our shoes.” He lamented that his wife did not have access to the drug sooner, given that her early symptoms appeared four years prior. Early intervention is crucial, as the toxic proteins linked to Alzheimer’s can accumulate in the brain long before any symptoms manifest.

As Sharon prepared to receive her historic infusion, she shared with CTV National News her struggle to comprehend her diagnosis. “In my day-to-day life, I feel like I’m fine,” she remarked. While her short-term memory has declined, her affection for her husband and their family remains as strong as ever. “I’m so fortunate to have met him,” she said, highlighting the importance of their relationship.

With Lecanemab now available, the Runges and other families facing Alzheimer’s have renewed hope for a better quality of life. As the medical community continues to explore the drug’s potential, including its effects on asymptomatic patients, the future may hold even more promise for those affected by this challenging disease.